DENV2 Genome Polyprotein Specific Neutra™ Antibody Products

Are you facing the challenges of dengue virus research, such as viral serotype specificity, complex neutralization assays, or the need for reliable tools to dissect DENV2 pathogenesis? Our DENV2 Genome Polyprotein Specific Neutra™ Antibody Products are engineered through advanced recombinant technology and high-throughput epitope mapping, empowering you to achieve precise detection, functional analysis, and accelerated therapeutic discovery against Dengue virus type 2.

Introduction to DENV2 Genome Polyprotein

The Dengue virus-2 Genome polyprotein is a critical single polypeptide precursor essential for viral replication and infectivity. Following translation, it is co- and post-translationally cleaved by both host and viral proteases into three structural proteins (Capsid C, precursor Membrane prM, and Envelope E) and seven non-structural (NS) proteins. This polyprotein orchestrates the entire viral life cycle. DENV2 is one of the four antigenically distinct serotypes of Dengue virus (Flavivirus genus), responsible for a significant global disease burden. The genome polyprotein is highly conserved within the serotype but exhibits key variations across serotypes, driving differential immune responses and disease severity.

• Structural Insights

The structural proteins assemble into an icosahedral envelope virion. The E protein, displayed on the virion surface, is the primary target for neutralizing antibodies. Its domain III (EDIII) is a major recognition site for highly specific neutralizing antibodies. Cryo-EM studies have resolved the dynamic conformational changes of the E protein during membrane fusion, informing epitope-targeted antibody design.

Fig.1 Dengue viral polyprotein and its anticipated membrane structure.¹

• Resistance and Signaling Pathways

DENV2 infection modulates host pathways such as the type I interferon (IFN) response, which it actively suppresses via NS proteins. The antibody-dependent enhancement (ADE) phenomenon, where sub-neutralizing antibodies can facilitate infection via Fcγ receptors, is a critical concern in vaccine and therapeutic antibody development, highlighting the need for potently neutralizing antibodies that avoid ADE.

• Clinical Impact

DENV2 infection can cause a spectrum of diseases, from self-limiting dengue fever to severe dengue (formerly dengue hemorrhagic fever/shock syndrome), characterized by plasma leakage, hemorrhage, and organ impairment.

• Antibodies Against DENV2 Genome Polyprotein
  Neutralizing antibodies targeting the DENV2 E protein, particularly those binding to quaternary epitopes or domain III, are paramount. They block viral attachment and fusion, directly inhibiting cellular entry. High-quality antibodies are indispensable for:
  • Mapping conformational epitopes and understanding neutralization mechanisms.
  • Differentiating DENV serotypes in research and diagnostics.
  • Evaluating vaccine-elicited immune responses.
  • Developing antibody-based therapeutics with strong neutralization potency and minimal ADE risk.

Applications of Anti-DENV2 Genome Polyprotein Neutralizing Antibodies

Fig.2 DENV particles exhibit infectious properties and are antigenically comparable to live dengue virus.²

• Vaccine Efficacy and Immunogenicity Assessment

Our high-affinity neutralizing antibodies serve as critical reference reagents for evaluating vaccine candidates. By performing plaque reduction neutralization tests (PRNT) or microneutralization assays, researchers can precisely quantify the titer and potency of neutralizing antibodies induced by DENV2 vaccines. This is essential for establishing correlates of protection and ensuring vaccine candidates elicit robust, serotype-specific immunity without inducing ADE-prone antibody profiles.

• Therapeutic Antibody Discovery and Development

Our antibodies are ideal tools for benchmarking in therapeutic discovery pipelines. They can be used in competitive binding assays (e.g., BLI, SPR) to characterize novel antibody candidates, identify epitope bins, and select lead molecules with superior neutralization breadth and potency against diverse DENV2 strains. This accelerates the development of monoclonal antibody therapies for the treatment of severe dengue.

• Advanced Pathogenesis and Host-Pathogen Interaction Studies

Utilize our antibodies in immunofluorescence, immunoprecipitation, and electron microscopy to visualize and quantify DENV2 antigen distribution in infected cells. This enables detailed study of viral replication complexes, assembly sites, and the interplay between viral proteins (e.g., NS1, E) and host factors, shedding light on mechanisms of virulence and immune evasion.

Our Anti-DENV2 Env Neutralizing Antibodies

Creative Biolabs delivers premium antibody solutions designed for the most demanding dengue research:

• High Specificity and Potency: Rigorously validated for exclusive reactivity with DENV2 antigens and superior neutralization activity in cell-based assays.
• Epitope-Defined: Antibodies are characterized for binding to key domains, providing tools for mechanistic studies.
• Low ADE Risk Profile: Selected and engineered to favor neutralization over FcγR binding, supporting safer therapeutic development.
• Multiplex Application Validated: Optimized for use in ELISA, Western Blot, Immunofluorescence, Neutralization Assays, and Flow Cytometry.
• Consistent and Reproducible: Produced under stringent quality controls to ensure batch-to-batch consistency for reliable, publishable results.

Creative Biolabs is your dedicated partner in advancing infectious disease research. We combine deep scientific knowledge with cutting-edge platform technologies to provide you with validated, high-performance antibody tools that accelerate discovery timelines. Contact our team, which is committed to supporting your project from concept to data generation.

References

1. Umareddy, Indira, et al. "Dengue virus serotype infection specifies the activation of the unfolded protein response." Virology journal 4.1 (2007): 91. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1186/1743-422X-4-91
2. Mattia, Kimberly, et al. "Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes." PloS one 6.11 (2011): e27252. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1371/journal.pone.0027252